Programs

To tackle the human health challenges that face the world today, the FNIH develops collaborations with top experts from government, industry, academia and the not-for-profit sector and provides a neutral environment where we can work productively toward a common goal.

The National Institutes of Health (NIH) is convening the 3rd Alzheimer's Disease-Related Dementia Summit, to be held on March 14-15, 2019 in Bethesda, Maryland. The 2019 Summit will bring together leading researchers, innovators and public advocates from academia, industry, the non-profit sector and NIH to discuss progress made on dementia related research and develop recommendations that will help facilitate new scientific discoveries.

In 2016, the AMP Executive Committee approved the planning of an AMP effort to confront the challenges presented by Parkinson’s disease (PD). This complements current efforts in the areas of Alzheimer’s disease, type 2 diabetes and the autoimmune disorders of rheumatoid arthritis and systemic lupus erythematosus (lupus). A critical component of this partnership is that all members have agreed to make the AMP Parkinson’s disease (AMP PD) data and analyses publicly available to the broad biomedical community.

National Institutes of Health convened the 3rd Alzheimer’s Disease (AD) Research Summit on March 1-2, 2018 in Bethesda, Maryland. The program built on the foundation laid by the 2012 and 2015 NIH AD Research Summits and the U.S. National Alzheimer’s Project Act (NAPA)/National Plan to Address AD.

National Research Summit on Dementia Care: Building Evidence for Services and Supports

On October 16-17, 2017, the National Advisory Council on Alzheimer’s Research, Care and Services held a two-day Summit on the NIH campus entitled: National Research Summit on Dementia Care: Building Evidence for Services and Supports. The purpose of the Summit was to address the growing need for evidence that improves the quality of care and support provided to persons with dementia and their caregivers.

Cognitive Aging Summit III will bring together experts in a variety of research fields to discuss the most cutting edge advances in our understanding of age-related brain and cognitive changes, with a particular focus on resilience and reserve.

The 2016 Alzheimer’s Disease-Related Dementias (ADRD) Summit was hosted by the National Institute of Neurological Disorders and Stroke (NINDS) in collaboration with the National Institute on Aging (NIA) and held March 29-30, 2016 at the Natcher Auditorium on the NIH Campus.

The Alzheimer’s Disease Neuroimaging Initiative (ADNI), is a landmark study that has profoundly influenced our understanding of Alzheimer’s disease by identifying the earliest changes in brain structure and function that signal its onset and progression.

ADNI was established to facilitate the development of effective treatments for Alzheimer’s disease by validating biomarkers for clinical trials and determining the relationships between the clinical, cognitive, imaging, genetic, and biochemical biomarker characteristics of AD.